• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

阿尔茨海默病神经退行性变标志物在无痴呆老年人中的纵向轨迹。

Longitudinal trajectories of Alzheimer's ATN biomarkers in elderly persons without dementia.

机构信息

Department of Neurology, Qingdao Municipal Hospital, Qingdao University, Qingdao, China.

Department of Neurology, Dalian Medical University, Dalian, China.

出版信息

Alzheimers Res Ther. 2020 May 11;12(1):55. doi: 10.1186/s13195-020-00621-6.

DOI:10.1186/s13195-020-00621-6
PMID:32393375
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7216714/
Abstract

BACKGROUND

Models of Alzheimer's disease (AD) pathophysiology posit that amyloidosis [A] precedes and accelerates tau pathology [T] that leads to neurodegeneration [N]. Besides this A-T-N sequence, other biomarker sequences are possible. This current work investigates and compares the longitudinal trajectories of Alzheimer's ATN biomarker profiles in non-demented elderly adults from the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort.

METHODS

Based on the ATN classification system, 262 individuals were identified before dementia diagnosis and accompanied by baseline and follow-up data of ATN biomarkers (CSF Aβ42, p-tau, and FDG-PET). We recorded the conversion processes in ATN biomarkers during follow-up, then analyzed the possible longitudinal trajectories and estimated the conversion rate and temporal evolution of biomarker changes. To evaluate how biomarkers changed over time, we used linear mixed-effects models.

RESULTS

During a 6-120-month follow-up period, there were four patterns of longitudinal changes in Alzheimer's ATN biomarker profiles, from all negative to positive through the course of the disease. The most common pattern is that A pathology biomarker first emerges. As well as the classical A-T-N sequence, other "A-first," "T-first," and "N-first" biomarker pathways were found. The N-A-T sequence had the fastest rate of pathological progression (mean 65.00 months), followed by A-T-N (mean 67.07 months), T-A-N (mean 68.85 months), and A-N-T sequences (mean 98.14 months).

CONCLUSIONS

Our current work presents a comprehensive analysis of longitudinal trajectories of Alzheimer's ATN biomarkers in non-demented elderly adults. Stratifying disease into subtypes depending on the temporal evolution of biomarkers will benefit the early recognition and treatment.

摘要

背景

阿尔茨海默病(AD)病理生理学模型假设淀粉样蛋白沉积[A]先于并加速导致神经退行性变[N]的 tau 病理学[T]。除了 A-T-N 序列外,还有其他可能的生物标志物序列。本研究旨在探讨和比较来自阿尔茨海默病神经影像学倡议(ADNI)队列的非痴呆老年人中阿尔茨海默病 ATN 生物标志物谱的纵向轨迹。

方法

根据 ATN 分类系统,在痴呆诊断前确定了 262 名个体,并伴有 ATN 生物标志物(CSF Aβ42、p-tau 和 FDG-PET)的基线和随访数据。我们记录了随访过程中 ATN 生物标志物的转化过程,然后分析了可能的纵向轨迹,并估计了生物标志物变化的转化率和时间演变。为了评估生物标志物随时间的变化,我们使用了线性混合效应模型。

结果

在 6-120 个月的随访期间,阿尔茨海默病 ATN 生物标志物谱存在四种纵向变化模式,从疾病过程中的所有阴性到阳性。最常见的模式是 A 病理学生物标志物首先出现。除了经典的 A-T-N 序列外,还发现了其他“ A 首先”、“ T 首先”和“ N 首先”的生物标志物途径。N-A-T 序列的病理进展速度最快(平均 65.00 个月),其次是 A-T-N(平均 67.07 个月)、T-A-N(平均 68.85 个月)和 A-N-T 序列(平均 98.14 个月)。

结论

本研究全面分析了非痴呆老年人阿尔茨海默病 ATN 生物标志物的纵向轨迹。根据生物标志物的时间演变将疾病分为亚型将有助于早期识别和治疗。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a5f/7216714/ab6b58c5bb84/13195_2020_621_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a5f/7216714/d342e3fb9224/13195_2020_621_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a5f/7216714/b48b707de60a/13195_2020_621_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a5f/7216714/ab6b58c5bb84/13195_2020_621_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a5f/7216714/d342e3fb9224/13195_2020_621_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a5f/7216714/b48b707de60a/13195_2020_621_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a5f/7216714/ab6b58c5bb84/13195_2020_621_Fig3_HTML.jpg

相似文献

1
Longitudinal trajectories of Alzheimer's ATN biomarkers in elderly persons without dementia.阿尔茨海默病神经退行性变标志物在无痴呆老年人中的纵向轨迹。
Alzheimers Res Ther. 2020 May 11;12(1):55. doi: 10.1186/s13195-020-00621-6.
2
Prognostic value of amyloid/tau/neurodegeneration (ATN) classification based on diagnostic cerebrospinal fluid samples for Alzheimer's disease.基于诊断性脑脊液样本的淀粉样蛋白/tau/神经退行性变(ATN)分类对阿尔茨海默病的预后价值。
Alzheimers Res Ther. 2021 Apr 20;13(1):84. doi: 10.1186/s13195-021-00817-4.
3
Alzheimer's disease diagnostic accuracy by fluid and neuroimaging ATN framework.基于液质和神经影像学阿尔茨海默病诊断准确性框架
CNS Neurosci Ther. 2024 Feb;30(2):e14357. doi: 10.1111/cns.14357. Epub 2023 Jul 12.
4
Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease.阿尔茨海默病患者纵向血浆神经丝轻链与神经退行性变的关系。
JAMA Neurol. 2019 Jul 1;76(7):791-799. doi: 10.1001/jamaneurol.2019.0765.
5
Longitudinal change in ATN biomarkers in cognitively normal individuals.认知正常个体中 ATN 生物标志物的纵向变化。
Alzheimers Res Ther. 2022 Sep 3;14(1):124. doi: 10.1186/s13195-022-01069-6.
6
FDG-PET as an independent biomarker for Alzheimer's biological diagnosis: a longitudinal study.FDG-PET 作为阿尔茨海默病生物学诊断的独立生物标志物:一项纵向研究。
Alzheimers Res Ther. 2019 Jun 29;11(1):57. doi: 10.1186/s13195-019-0512-1.
7
Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model.阿尔茨海默病进展中淀粉样蛋白和 tau 生物标志物的相互预测关系:一个经验模型。
J Neurosci. 2019 Sep 11;39(37):7428-7437. doi: 10.1523/JNEUROSCI.1056-19.2019. Epub 2019 Jul 26.
8
Exploring the ATN classification system using brain morphology.探索使用大脑形态学的 ATN 分类系统。
Alzheimers Res Ther. 2023 Mar 13;15(1):50. doi: 10.1186/s13195-023-01185-x.
9
Prognostic value of ATN Alzheimer biomarkers: 60-month follow-up results from the Argentine Alzheimer's Disease Neuroimaging Initiative.急性肾小管坏死型阿尔茨海默病生物标志物的预后价值:来自阿根廷阿尔茨海默病神经影像倡议的60个月随访结果。
Alzheimers Dement (Amst). 2020 May 22;12(1):e12026. doi: 10.1002/dad2.12026. eCollection 2020.
10
Longitudinal structural cerebral changes related to core CSF biomarkers in preclinical Alzheimer's disease: A study of two independent datasets.与临床前阿尔茨海默病核心 CSF 生物标志物相关的纵向结构脑变化:两项独立数据集研究。
Neuroimage Clin. 2018 Apr 16;19:190-201. doi: 10.1016/j.nicl.2018.04.016. eCollection 2018.

引用本文的文献

1
From Better Diagnostics to Earlier Treatment: The Rapidly Evolving Alzheimer's Disease Landscape.从更好的诊断到更早的治疗:快速演变的阿尔茨海默病格局
Medicina (Kaunas). 2025 Aug 14;61(8):1462. doi: 10.3390/medicina61081462.
2
Integrating neuroinflammation biomarkers into the ATN(X) framework: Advances in Alzheimer's pathogenesis, diagnosis, and insights from non-human primate models.将神经炎症生物标志物纳入急性肾损伤(X)框架:阿尔茨海默病发病机制、诊断的进展以及非人灵长类动物模型的见解
Alzheimers Dement. 2025 Aug;21(8):e70472. doi: 10.1002/alz.70472.
3
Sex Differences in Vulnerability to Tau Pathology: Impact on Cognitive Decline.

本文引用的文献

1
Frequency and longitudinal clinical outcomes of Alzheimer's AT(N) biomarker profiles: A longitudinal study.阿尔茨海默病 AT(N)生物标志物谱的频率和纵向临床结局:一项纵向研究。
Alzheimers Dement. 2019 Sep;15(9):1208-1217. doi: 10.1016/j.jalz.2019.05.006. Epub 2019 Aug 6.
2
Association of Amyloid and Tau With Cognition in Preclinical Alzheimer Disease: A Longitudinal Study.临床前阿尔茨海默病中淀粉样蛋白和tau蛋白与认知的关联:一项纵向研究。
JAMA Neurol. 2019 Aug 1;76(8):915-924. doi: 10.1001/jamaneurol.2019.1424.
3
Subthreshold Amyloid Predicts Tau Deposition in Aging.
tau蛋白病变易感性的性别差异:对认知衰退的影响。
medRxiv. 2025 May 26:2025.05.25.25328324. doi: 10.1101/2025.05.25.25328324.
4
Differences in Glucose Metabolism Between Single Memory Domain and Multidomain Subjective Cognitive Decline: A Longitudinal Study From SILCODE.单一记忆领域与多领域主观认知衰退之间的葡萄糖代谢差异:来自SILCODE的纵向研究
CNS Neurosci Ther. 2025 May;31(5):e70264. doi: 10.1111/cns.70264.
5
Energy metabolism in health and diseases.健康与疾病中的能量代谢。
Signal Transduct Target Ther. 2025 Feb 18;10(1):69. doi: 10.1038/s41392-025-02141-x.
6
Clinical Diagnoses and Characterization of Patients With Amyloid-Negative Amyloid-Beta, p-Tau, and Neurofilament Light Chain (ATN) Profiles.淀粉样蛋白阴性的淀粉样β蛋白、磷酸化tau蛋白和神经丝轻链(ATN)谱患者的临床诊断与特征分析
Cureus. 2024 Dec 17;16(12):e75874. doi: 10.7759/cureus.75874. eCollection 2024 Dec.
7
The clinical importance of suspected non-Alzheimer disease pathophysiology.疑似非阿尔茨海默病病理生理学的临床重要性。
Nat Rev Neurol. 2024 Jun;20(6):337-346. doi: 10.1038/s41582-024-00962-y. Epub 2024 May 9.
8
Cerebrospinal fluid reference proteins increase accuracy and interpretability of biomarkers for brain diseases.脑脊液参考蛋白提高了脑部疾病生物标志物的准确性和可解释性。
Nat Commun. 2024 May 1;15(1):3676. doi: 10.1038/s41467-024-47971-5.
9
Neuropathology, Neuroimaging, and Fluid Biomarkers in Alzheimer's Disease.阿尔茨海默病中的神经病理学、神经影像学和生物标志物
Diagnostics (Basel). 2024 Mar 27;14(7):704. doi: 10.3390/diagnostics14070704.
10
Estimating Dementia Onset: AT(N) Profiles and Predictive Modeling in Mild Cognitive Impairment Patients.估计痴呆发病时间:轻度认知障碍患者的 AT(N) 特征和预测模型。
Curr Alzheimer Res. 2024;20(11):778-790. doi: 10.2174/0115672050295317240223162312.
亚阈值淀粉样蛋白可预测衰老中的 Tau 沉积。
J Neurosci. 2018 May 9;38(19):4482-4489. doi: 10.1523/JNEUROSCI.0485-18.2018. Epub 2018 Apr 23.
4
NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease.NIA-AA 研究框架:迈向阿尔茨海默病的生物学定义。
Alzheimers Dement. 2018 Apr;14(4):535-562. doi: 10.1016/j.jalz.2018.02.018.
5
Memory decline accompanies subthreshold amyloid accumulation.记忆衰退伴随着亚阈值淀粉样蛋白积累。
Neurology. 2018 Apr 24;90(17):e1452-e1460. doi: 10.1212/WNL.0000000000005354. Epub 2018 Mar 23.
6
Ageing, neurodegeneration and brain rejuvenation.衰老、神经退行性变与大脑年轻化
Nature. 2016 Nov 10;539(7628):180-186. doi: 10.1038/nature20411.
7
Transition rates between amyloid and neurodegeneration biomarker states and to dementia: a population-based, longitudinal cohort study.淀粉样蛋白与神经退行性变生物标志物状态之间以及向痴呆症转变的速率:一项基于人群的纵向队列研究。
Lancet Neurol. 2016 Jan;15(1):56-64. doi: 10.1016/S1474-4422(15)00323-3. Epub 2015 Nov 18.
8
Tracking the earliest pathologic changes in Alzheimer disease.追踪阿尔茨海默病最早的病理变化。
Neurology. 2014 May 6;82(18):1576-7. doi: 10.1212/WNL.0000000000000392. Epub 2014 Apr 4.
9
The amyloid hypothesis, time to move on: Amyloid is the downstream result, not cause, of Alzheimer's disease.淀粉样蛋白假说,是时候向前看了:淀粉样蛋白是阿尔茨海默病的下游结果,而不是病因。
Alzheimers Dement. 2014 May;10(3):372-80. doi: 10.1016/j.jalz.2013.11.003. Epub 2014 Feb 28.
10
Amyloid-β and tau: the trigger and bullet in Alzheimer disease pathogenesis.淀粉样蛋白-β 和 tau:阿尔茨海默病发病机制中的扳机和子弹。
JAMA Neurol. 2014 Apr;71(4):505-8. doi: 10.1001/jamaneurol.2013.5847.